Crystalline forms of a factor xa inhibitor
AssigneeBristol-Myers Squibb Company
InventorsMichael J. Orwat, Mary F. Malley, Roxana Schlam, Steven R. Fabian, Bing-Shiou Yang, Victor W. Rosso
Life of this patent
Estimating the term…
Abstract
The instant invention provides crystalline forms of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one and its solvates thereof, processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
Claims4
A pharmaceutical composition comprising a therapeutically effective amount of crystalline Form N-1 of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one and a pharmaceutically acceptable carrier.
A method for treating a thromboembolic disorder, comprising:
- administering to a patient in need thereof a therapeutically effective amount of crystalline Form N-1 of 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo [3,4-c]pyridin-7-one.
Dependencies are inferred from the claim text.